Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide

In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytoge...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Göhring, Gudrun, Giagounidis, Aristoteles, Büsche, Guntram, Hofmann, Winfried, Kreipe, Hans Heinrich, Fenaux, Pierre, Hellström-Lindberg, Eva, Schlegelberger, Brigitte
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2011
Materias:
Brief Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031702/
https://ncbi.nlm.nih.gov/pubmed/21109690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.026658
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares